請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53770
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 李財坤(Tsai-Kun Li) | |
dc.contributor.author | Chia-Hao Yen | en |
dc.contributor.author | 嚴家濠 | zh_TW |
dc.date.accessioned | 2021-06-16T02:29:20Z | - |
dc.date.available | 2023-07-31 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-07-31 | |
dc.identifier.citation | Azarova, A. M., Y. L. Lyu, C. P. Lin, Y. C. Tsai, J. Y. Lau, J. C. Wang and L. F. Liu (2007). 'Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies.' Proc Natl Acad Sci U S A 104(26): 11014-11019. Bergerat, A., B. de Massy, D. Gadelle, P. C. Varoutas, A. Nicolas and P. Forterre (1997). 'An atypical topoisomerase II from Archaea with implications for meiotic recombination.' Nature 386(6623): 414-417. Bodley, A., L. F. Liu, M. Israel, R. Seshadri, Y. Koseki, F. C. Giuliani, S. Kirschenbaum, R. Silber and M. Potmesil (1989). 'DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.' Cancer Res 49(21): 5969-5978. Cao, R., W. Peng, H. Chen, Y. Ma, X. Liu, X. Hou, H. Guan and A. Xu (2005). 'DNA binding properties of 9-substituted harmine derivatives.' Biochem Biophys Res Commun 338(3): 1557-1563. Cao, R., W. Peng, Z. Wang and A. Xu (2007). 'beta-Carboline alkaloids: biochemical and pharmacological functions.' Curr Med Chem 14(4): 479-500. Chen, W., J. Qiu and Y. M. Shen (2012). 'Topoisomerase IIalpha, rather than IIbeta, is a promising target in development of anti-cancer drugs.' Drug Discov Ther 6(5): 230-237. Chikamori, K., A. G. Grozav, T. Kozuki, D. Grabowski, R. Ganapathi and M. K. Ganapathi (2010). 'DNA topoisomerase II enzymes as molecular targets for cancer chemotherapy.' Curr Cancer Drug Targets 10(7): 758-771. Deweese, J. E. and N. Osheroff (2009). 'The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing.' Nucleic Acids Res 37(3): 738-748. Funayama, Y., K. Nishio, K. Wakabayashi, M. Nagao, K. Shimoi, T. Ohira, S. Hasegawa and N. Saijo (1996). 'Effects of beta- and gamma-carboline derivatives of DNA topoisomerase activities.' Mutat Res 349(2): 183-191. Gilroy, K. L. and C. A. Austin (2011). 'The impact of the C-terminal domain on the interaction of human DNA topoisomerase II alpha and beta with DNA.' PLoS One 6(2): e14693. Hande, K. R. (1998). 'Etoposide: four decades of development of a topoisomerase II inhibitor.' Eur J Cancer 34(10): 1514-1521. Harker, W. G., D. L. Slade, W. S. Dalton, P. S. Meltzer and J. M. Trent (1989). 'Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.' Cancer Res 49(16): 4542-4549. Herraiz, T. and C. Chaparro (2006). 'Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee.' Life Sci 78(8): 795-802. Huang, K. C., H. Gao, E. F. Yamasaki, D. R. Grabowski, S. Liu, L. L. Shen, K. K. Chan, R. Ganapathi and R. M. Snapka (2001). 'Topoisomerase II poisoning by ICRF-193.' J Biol Chem 276(48): 44488-44494. Ikeda, R., M. Kurosawa, T. Okabayashi, A. Takei, M. Yoshiwara, T. Kumakura, N. Sakai, O. Funatsu, A. Morita, M. Ikekita, Y. Nakaike and T. Konakahara (2011). '3-(3-Phenoxybenzyl)amino-beta-carboline: a novel antitumor drug targeting alpha-tubulin.' Bioorg Med Chem Lett 21(16): 4784-4787. Jensen, P. B. and M. Sehested (1997). 'DNA topoisomerase II rescue by catalytic inhibitors: a new strategy to improve the antitumor selectivity of etoposide.' Biochem Pharmacol 54(7): 755-759. Ju, B. G., V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass and M. G. Rosenfeld (2006). 'A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription.' Science 312(5781): 1798-1802. Kaufmann, W. K. (1998). 'Human topoisomerase II function, tyrosine phosphorylation and cell cycle checkpoints.' Proc Soc Exp Biol Med 217(3): 327-334. Larsen, A. K., A. E. Escargueil and A. Skladanowski (2003). 'Catalytic topoisomerase II inhibitors in cancer therapy.' Pharmacol Ther 99(2): 167-181. Lee, C. H., M. Y. Hsieh, L. W. Hsin, H. C. Chen, S. C. Lo, J. R. Fan, W. R. Chen, H. W. Chen, N. L. Chan and T. K. Li (2012). 'Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles.' Biochem Pharmacol 83(9): 1208-1216. Liu, L. F. (1989). 'DNA topoisomerase poisons as antitumor drugs.' Annu Rev Biochem 58: 351-375. Lyu, Y. L., J. E. Kerrigan, C. P. Lin, A. M. Azarova, Y. C. Tsai, Y. Ban and L. F. Liu (2007). 'Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.' Cancer Res 67(18): 8839-8846. Madle, E., G. Obe, J. Hansen and H. Ristow (1981). 'Harman and norharman: induction of sister-chromatid exchanges in human peripheral lymphocytes in vitro and interaction with isolated DNA.' Mutat Res 90(4): 433-442. Moloudizargari, M., P. Mikaili, S. Aghajanshakeri, M. H. Asghari and J. Shayegh (2013). 'Pharmacological and therapeutic effects of Peganum harmala and its main alkaloids.' Pharmacogn Rev 7(14): 199-212. Mori, T., A. Nakagawa, N. Kobayashi, M. W. Hashimoto, K. Wakabayashi, K. Shimoi and N. Kinae (1998). '3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole (Trp-P-1) sensitizes mammalian cells to UV radiation by causing the S-phase arrest, not by inhibiting the repair of DNA damage as observed in Escherichia coli.' J Radiat Res 39(1): 21-33. Nitiss, J. L. (2009). 'Targeting DNA topoisomerase II in cancer chemotherapy.' Nat Rev Cancer 9(5): 338-350. Pedersen-Bjergaard, J., M. K. Andersen, D. H. Christiansen and C. Nerlov (2002). 'Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.' Blood 99(6): 1909-1912. Pendleton, M., R. H. Lindsey, Jr., C. A. Felix, D. Grimwade and N. Osheroff (2014). 'Topoisomerase II and leukemia.' Ann N Y Acad Sci 1310: 98-110. Roca, J., R. Ishida, J. M. Berger, T. Andoh and J. C. Wang (1994). 'Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp.' Proc Natl Acad Sci U S A 91(5): 1781-1785. Sobhani, A. M., S. A. Ebrahimi and M. Mahmoudian (2002). 'An in vitro evaluation of human DNA topoisomerase I inhibition by Peganum harmala L. seeds extract and its beta-carboline alkaloids.' J Pharm Pharm Sci 5(1): 19-23. Song, Y., D. Kesuma, J. Wang, Y. Deng, J. Duan, J. H. Wang and R. Z. Qi (2004). 'Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.' Biochem Biophys Res Commun 317(1): 128-132. Speyer, J. L., M. D. Green, A. Zeleniuch-Jacquotte, J. C. Wernz, M. Rey, J. Sanger, E. Kramer, V. Ferrans, H. Hochster, M. Meyers and et al. (1992). 'ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.' J Clin Oncol 10(1): 117-127. Tan, K. B., T. E. Dorman, K. M. Falls, T. D. Chung, C. K. Mirabelli, S. T. Crooke and J. Mao (1992). 'Topoisomerase II alpha and topoisomerase II beta genes: characterization and mapping to human chromosomes 17 and 3, respectively.' Cancer Res 52(1): 231-234. Vignoni, M., F. A. Rasse-Suriani, K. Butzbach, R. Erra-Balsells, B. Epe and F. M. Cabrerizo (2013). 'Mechanisms of DNA damage by photoexcited 9-methyl-beta-carbolines.' Org Biomol Chem 11(32): 5300-5309. Wang, J. C. (2002). 'Cellular roles of DNA topoisomerases: a molecular perspective.' Nat Rev Mol Cell Biol 3(6): 430-440. Wilstermann, A. M., R. P. Bender, M. Godfrey, S. Choi, C. Anklin, D. B. Berkowitz, N. Osheroff and D. E. Graves (2007). 'Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.' Biochemistry 46(28): 8217-8225. Wu, C. C., T. K. Li, L. Farh, L. Y. Lin, T. S. Lin, Y. J. Yu, T. J. Yen, C. W. Chiang and N. L. Chan (2011). 'Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.' Science 333(6041): 459-462. Yang, X., W. Li, E. D. Prescott, S. J. Burden and J. C. Wang (2000). 'DNA topoisomerase IIbeta and neural development.' Science 287(5450): 131-134. Yang, Y. C., H. Y. Chou, T. L. Shen, W. J. Chang, P. H. Tai and T. K. Li (2013). 'Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis.' Antioxid Redox Signal 18(10): 1129-1140. Yeh, E. T. and C. L. Bickford (2009). 'Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.' J Am Coll Cardiol 53(24): 2231-2247. Zhang, S., X. Liu, T. Bawa-Khalfe, L. S. Lu, Y. L. Lyu, L. F. Liu and E. T. Yeh (2012). 'Identification of the molecular basis of doxorubicin-induced cardiotoxicity.' Nat Med 18(11): 1639-1642. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53770 | - |
dc.description.abstract | 人類第二型拓樸異構酶(Top2), 是細胞中重要調控蛋白,主要利用其可以解決不同DNA的拓樸構型的酵素能力,幫忙解決在細胞DNA複製和RNA轉錄過程伴隨產生的DNA超螺旋構造,使過程能順利進行。另外,針對其細胞生理的重要性,目前臨床上已發展許多抑制第二型拓樸異構酶的藥物;根據藥物作用機制目前分為兩類: (1) Top2 poisons,例如etoposide(VP-16)及doxorubicin,當Top2利用其活性中心的酪胺酸與DNA形成共價鍵,並產生DNA雙股螺旋的斷裂,此時藥物會穩定這個酵素-DNA共價附合體,稱之為切割複合體(cleavable complex),進而累積染色體DNA的斷裂最終引發癌細胞的死亡。(2) Top2 inhibitor,例如dexrazoxane(ICRF-187),此類藥物不會穩定切割複合體而使DNA產生斷裂,相對的是抑制在酵素催化周期的其他步驟,例如ICRF-193它會在酵素活性周期中抑制ADP的釋出,使DNA無法離開進而阻斷酵素活性與作用,甚至降低切割複合體的形成。在人類的細胞中,已知表現兩種亞型的第二型拓樸異構酶:(1) Top2α -α亞型同功酵素(isozyme)主要調控DNA複製及染色體分離,在快速分裂中的細胞會大量表現,因此針對癌細胞的快速複製特性,為目前抗癌藥物主要針對的標的。(2) Top2β- | zh_TW |
dc.description.abstract | Human topoisomerase II (hTop2) proteins solve topological problems during DNA replication, transcription, chromosome condensation and segregation, thereby playing essential roles in cells. Owing to the essential functions, Top2s have been identified to be excellent targets for antibiotics and anti-cancer drugs. Based on the mechanisms of action, two groups of hTop2-targeting compounds have been classified, namely Top2 poison and inhibitor: (i) hTop2 poisons, such as etoposide (VP-16) and doxorubicin, stabilize hTop2-DNA-drug covalent ternary complex (cleavable complex, hTop2cc) and induce DNA double-stranded break, (ii) hTop2 inhibitors such as dexrazoxane (ICRF-187) only interfere catalytic activity and antagonize hTop2cc-mediated DNA break without hTop2cc induction. It shall be noted that there are two hTop2 isoforms with distinctive cellular functions and pharmacological properties: (i) hTop2α plays the major role for cancer cell killing of Top2 poison (ii) hTop2β is responsible for its side effects such as the doxorubicin-mediated cardiotoxicity and VP16-induced 2nd malignancies. Here, we proposed two specific aims: (I) To identify hTop2α-specific poisons for maximizing the efficacy of cancer cell killing with reduced side effects; and (II) To identify hTop2β-specific inhibitors to antagonize side effects of clinically useful hTop2 drugs. In this regards, previously studies have shown that β-carboline derivatives could not only inhibit hTop2, but also have potential isozyme selectivity against monoamine oxidases (MAOs). Thus, we had first chosen β-carbolines and used cytotoxicity and hTop2 relaxation assays to screen 27 derivatives to categorize desired poison and inhibitor candidates based on obtained results of above assays. We then performed the comet assay to detect their ability of induce hTop2-mediated DNA damage and others in vitro assays with purified hTop2 isozymes for further validation. For hTop2-poison candidates, we found two potential poisons. One is H2-53, however, despite of it has a higher cytotoxicity and induces DNA damage, H2-53’s target is not hTop2. Another is DH-337, which induced Top2-mediated DNA damages, and it was mainly from hTop2β. For Top2-inhibitor candidates, we identified that H9-1, H9-2 and H9-3 those have lower cytotoxicity and could also inhibit Top2 relaxation ability. Using the comet assay-based antagonizing experiments, we observed that H9-1 could antagonize the VP-16-induced chromosomal DNA breaks most efficiently among the above three agents. Coupled with the isozyme-knockdown experiments, we found that the antagonized ability of H9-1 is similarly against Top2α and Top2β. Therefore, we suggested that H9-1 could antagonize on Top2, but unfortunately without the isozyme preference. Together, studied on these β-carboline agents and their structure-function relationship, we have gained the following notions. (1) If there is a positive charge on the structure of carboline ring, the agents seem to have higher cytotoxicity. (2) If these agents have longer side chains on the N-3 of carboline ring, it may become structural obstacles for agents to target on Top2. Further investigation is necessary to identify the isozyme preference of these candidate hits and corresponding action mechanism(s) of Top2 targeting. Nevertheless, our study shall provide some revenues for the search of hTop2 isozyme-specific targeting intervention. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:29:20Z (GMT). No. of bitstreams: 1 ntu-104-R02445116-1.pdf: 2459018 bytes, checksum: 486af0ffe8f2efa4fe876e3860204d62 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 口試委員審定書 I 致謝 II 中文摘要 III ABSTRACT V INTRODUCTION 1 1. DNA Topoisomerases 1.1 Type II DNA topoisomerases 1.2 Human topoisomerase II and its catalytic activity 1.3 Isozyme difference of human topoisomerase II 2. Topoisomerase II acts as anti-cancer drugs targets 2.1 Mechanisms of Top2 inhibition 2.2 Classification of Top2 clinical cancer drugs 3. Top2 isozymes play different roles at antitumor efficacy 3.1 The significance to identify isozymes-specific agents 3.2 Roles of topoisomerase II in chemotherapy and its side-effects 4. Beta-carboline derivatives 4.1 Inhibition on topoisomerases 4.2 Potential of isoymes preferences based on structure-activity relationship (SAR) SPECIFIC AIMS 11 MATERIALS AND METHODS 13 - Chemical compounds, plasmid and cell lines - Cytotoxicity assay (4-day MTT assay) - Topoisomerase II (Top2) relaxation assay - Alkaline single cell gel-electrophroesis (comet) assay - In vitro Top2 trapping assay - In vivo complexes of Enzyme (ICE) bioassay - DNA binding assays - Lentivirus-based RNA interference (RNAi) RESULTS 18 1. β-carboline derivatives can inhibit Top2 relaxation activity 2. β-carboline derivatives had the potential to induce Top2-mediated DNA damages and act as a Top2-poison 2.1 DH-337 could induce DNA damage which had a part from Top2-mediated 2.2 The four β-carboline derivatives would not interact with DNA 2.3 DH-337 could trap on the formation of Top2β-cleavage complex 2.4 DH337 could directly induce the formation of Top2β-cleavage complex 2.5 DH-337 could target on Top2β | |
dc.language.iso | en | |
dc.title | 探討Beta-carboline衍生物對於第二型拓樸異構酶亞型之細胞生理作用與酵素專一性 | zh_TW |
dc.title | Identify topoisomerase II isozyme-specific targeting agents from β-carboline derivatives | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 詹迺立(Nei-Li Chan),顧記華(Jih-Hwa Guh) | |
dc.subject.keyword | 第二型DNA拓樸異構?,致癌細胞毒性,藥物酵素專一性,Beta-carboline衍生物, | zh_TW |
dc.subject.keyword | topoisomerase II,cancer cell-killing,β-carboline deriviatives,isozyme-specific targenting agents, | en |
dc.relation.page | 59 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-07-31 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 2.4 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。